Institutional ticker directory tracking stock mentions, long/short ideas, and high-conviction pitches extracted from quarterly hedge fund letters.
| Ticker | Company | Sector | Industry | Pitches | Stance |
|---|---|---|---|---|---|
| Fund / Manager | Thesis Excerpt | Stance | Period / Date | Action |
|---|---|---|---|---|
Pelican Bay Capital Management Tyler Hardt, CFA | “On the negative side, we suffered only one real setback. One of our newer holdings, Zoetis (ZTS), fell sharply after its first-quarter earnings report. The company's legacy dermatology treatments and parasite franchises continue to lose share to lower-priced competition, as pet owners struggling with macroeconomic headwinds try to reduce veterinary spending. We believed these headwinds were already well understood, and the magnitude of the sell-off following their Q1 earnings release took us by surprise. However, we continue to believe that animal health spending will increase and that Zoetis is well positioned with a strong product pipeline to support high single-digit sales growth for years to come. Consequently, we added to our position after the sell-off.” | NEUTRAL | Q2 2026 Aug 13, 2026 | View Pitch |
Polen Capital - Focus Growth Dan Davidowitz | “We sold Zoetis. Zoetis remains the global leader in animal health and retains many of the characteristics we admire: strong brands, scale, recurring demand, and a long runway for innovation. However, the business has slowed due in part to competitive entry in dermatology, an important growth area for the company. We expect Zoetis to return to better growth over time, supported by a pipeline of new product launches, but we think that acceleration is unlikely to restore revenue growth to high-single-digit levels until late next year. We will continue to follow the company closely and would consider reinvesting if the acceleration becomes more visible. For now, we believe the capital is better deployed into businesses that we think have stronger current momentum, including ATI, GE Aerospace, and GE Vernova.” | NEUTRAL | Q2 2026 Jul 30, 2026 | View Pitch |
Polen Capital - Global Growth Buyside Damon Ficklin | “Zoetis was the largest detractor during the quarter as the market continued to quickly penalize any disappointment in business momentum. The company remains the world's leading animal health business, with the broadest portfolio, largest footprint, and a long history of bringing human health innovations into animal care. However, increased competition in companion animal dermatology has pressured growth, pricing power, and confidence in the company's future margin structure. At the same time, Zoetis is facing cyclical pressure as pet owners appear to be delaying or trading down care. While the company has a healthy pipeline that should support stronger growth over time, the timing of that reacceleration remains uncertain. As a result, we sold our position during the quarter. Zoetis remains the global leader in animal health and retains many of the characteristics we admire: strong brands, scale, recurring demand, and a long runway for innovation. However, the business has slowed due in part to competitive entry in dermatology, an important growth area for the company. We expect Zoetis to return to better growth over time, supported by a pipeline of new product launches, but we think that acceleration is unlikely to restore revenue growth to high-single-digit levels until late next year. We will continue to follow the company closely and would consider reinvesting if the acceleration becomes more visible. For now, we believe the capital is better deployed into businesses that we think have stronger current momentum.” | NEUTRAL | Q2 2026 Jul 30, 2026 | View Pitch |
Platinum International Brands Fund Nik Dvornak | “Our worst performer was Zoetis (-35%). Simply, we got this wrong. Zoetis makes medicines for pets and livestock and has long been the great innovator of its field, having pioneered and dominated the huge markets for canine dermatology and three-in-one parasiticides. Unfortunately, its rivals have caught up and its commercial response has disappointed. In fairness, it likely expected its promising new arthritis treatment to comfortably offset any erosion. However, a social media scare campaign derailed its US launch largely because their commercial response was again inadequate. Zoetis has a superb research engine and an exciting pipeline; we simply misjudged its ability to execute commercially. We have sold the bulk of our holding, as its next launch is at best a year away.” | NEUTRAL | Q2 2026 Jul 25, 2026 | View Pitch |
Brown Advisors Global Leaders Strategy Mike Poggi | “We also had specific errors of commission in Zoetis and Workday, both of which have now been exited. Zoetis observed increased competition across its main franchises and most recently also saw generic competition in therapeutic categories. We exited the company during the quarter. We exited Zoetis in May. We were attracted to the investment due to its position as the largest pure-play animal health company, benefiting from significant scale in R&D and as the highest-quality marketer to veterinarians and livestock producers, which increases switching costs. Our investment in Zoetis began to face increased growth headwinds in 2025 due to incremental competition in its industry-leading dermatology and Simparica Trio products. Additionally, the launch of Librela—the first available therapy for osteoarthritis pain in dogs—underperformed our expectations. Furthermore, we have observed increased competition across Zoetis's main franchises and, most recently, Zoetis also saw generic competition in therapeutic categories. As such, we see our investment thesis in Zoetis as broken and have fully exited the position.” | BEAR | Q2 2026 Jul 22, 2026 | View Pitch |
Moon Capital Management David Moon | “We added one new stock to the portfolio last quarter, Zoetis. (Our average purchase price was about $73.20/share.) Zoetis is the world's largest pure-play animal health company. We have long viewed Zoetis as one of the highest-quality businesses in healthcare (albeit for mostly four-legged patients), and the company has generally been valued accordingly. However, temporary concerns around slower companion animal growth and increased competitive pressures created an opportunity to purchase the company at an attractive price. After trading above 30 times earnings for much of the past decade, Zoetis now has a P/E of less than 11x, a valuation we believe significantly understates the quality, durability, and long-term earnings power of the business. The animal health industry is attractive as it combines the defensive characteristics of healthcare investing with a more favorable industry structure than traditional pharmaceuticals. Within this landscape, Zoetis has established one of the strongest competitive positions in the industry. The company holds leading positions in major therapeutic categories, with a broad portfolio spanning hundreds of products across companion animals and livestock, along with a global commercial infrastructure that would be extremely difficult for competitors to replicate. Zoetis has consistently extended the life of its key franchises through innovation, including new formulations, expanded indications, and geographic expansion. The company's leading franchises in parasiticides, dermatology, and pain management provide a strong foundation for future growth. Zoetis also maintains one of the strongest innovation engines in animal health. At our purchase price, we were able to acquire a business with industry-leading margins, strong free cash flow generation, and a dominant competitive position for less than 11x earnings. Additionally, Zoetis' remaining $1.8 billion share repurchase authorization provides an attractive opportunity to significantly enhance per-share value at a time when the stock is trading at a depressed valuation. We believe Zoetis represents one of those opportunities: a high-quality company experiencing a period of slower growth rather than a permanent impairment of its competitive position.” | NEUTRAL | Q2 2026 Jul 21, 2026 | View Pitch |
Pelican Bay Capital Management Tyler Hardt, CFA | “Zoetis is the leading pharmaceutical and vaccine developer in the global animal health market. The company has delivered consistent organic growth above industry averages driven by a deep R&D pipeline and strong veterinary sales force. Near-term investor concerns around newer product launches pressured the stock in 2025. We believe these concerns are temporary and that Zoetis' long-term growth trajectory remains intact. We initiated our position near the bottom of our intrinsic value range despite typically requiring a wider margin of safety. BSD Analysis: Zoetis enters 2026 with a commitment to consistent shareholder returns, recently approving a 6% increase in its quarterly dividend. As a Fortune 500 leader in animal health, the company benefits from a diversified portfolio of medicines, vaccines, and diagnostics used in over 100 countries. The long-term investment case is supported by the "humanization of pets" trend and the essential nature of livestock productivity in the global food supply chain. Management's forward-looking views remain positive, focusing on a robust R&D pipeline to sustain its market-leading margins. While the animal health sector can be sensitive to broader economic shifts, Zoetis' scale and direct-to-veterinarian model provide a formidable competitive moat. The company remains a top pick for those seeking defensive growth within the broader healthcare and agriculture sectors.” | BULL | Q4 2025 Jan 22, 2026 | View Pitch |
Impax US Sustainable Economy Fund Scott LaBreche, Christine Cappabianca | “Zoetis is held due to its attractive sustainability opportunity profile and strong governance. During the quarter, there was disappointment in the company's Q3 earnings update. While Zoetis has a full pipeline of new products to launch, there is some time before these can materially accelerate revenue growth. The company faces increasing competition across some established franchises. Its key canine arthritis pain product Librela declined more than expected due to side-effect perception issues. BSD Analysis: Zoetis dominates animal health with a portfolio that benefits from rising pet humanization and global protein demand. Veterinary care is less price-sensitive than human healthcare, supporting margins. Recurring treatments and diagnostics drive stable revenue. Investors worry about growth normalization and miss the durability of demand. R&D and commercial scale create real barriers to entry. International expansion extends the runway. This is healthcare economics applied to animals, and it compounds quietly.” | BEAR | Q4 2025 Jan 21, 2026 | View Pitch |
The Bristol Gate U.S. Equity Strategy Achilleas Taxildaris | “Zoetis (ZTS) released earnings earlier in November and while earnings per share was ahead of consensus, sales trailed modestly. The company also lowered its annual guidance, leading to a significant stock decline after the release. Throughout the year, ZTS struggled with fewer US veterinarian visits, new competition in key markets and ongoing negative social media coverage related to the company's osteoarthritis pain drugs. In December, the board of directors declared a dividend increase of 6% from the quarterly rate paid in 2025. We exited the position prior to year end because of deteriorating dividend growth. We held ZTS for over 6 years and until 2025, the company had an annualized dividend growth rate of 22% during our holding period. BSD Analysis: Zoetis dominates animal health by selling products people don't think twice about paying for. Pet humanization continues to push spend higher regardless of economic conditions. The company benefits from recurring treatments, vaccines, and diagnostics with real pricing power. Competition exists, but regulatory barriers and brand trust keep the field rational. Margins are consistently strong because R&D translates directly into differentiated products. Livestock adds diversification, but pets are the real growth engine. Zoetis doesn't need innovation miracles — just steady execution. This is defensive growth done right. A rare healthcare name that sleeps well at night.” | BEAR | Q4 2025 Dec 31, 2025 | View Pitch |
Diamond Hill Mid Cap Anthony Philipp | “Zoetis is a leader in the animal health market with leading products for companion animals and livestock. The company has a broad portfolio with multiple growth drivers and a strong pipeline to address several undertreated pet conditions. Concerns about one of its arthritis drugs used in dogs have pressured the share price recently, allowing us to introduce a position below our estimate of intrinsic value. BSD Analysis: Zoetis dominates animal health in a world where pets are treated like family and livestock efficiency matters more every year. Veterinary spending is far less price-sensitive than human healthcare, which quietly supports margins. Recurring treatments and diagnostics create annuity-like revenue streams. Investors worry about growth normalization and miss the durability of chronic care demand. R&D scale and global distribution form barriers smaller competitors can't breach. Emerging markets extend the runway beyond North America. This is healthcare economics applied to animals, and it compounds quietly while sentiment looks elsewhere.” | BULL | Q4 2025 Dec 31, 2025 | View Pitch |
Diamond Hill Large Cap Strategy Austin Hawley | “Pet and livestock pharmaceutical manufacturer Zoetis underperformed in Q4 after reducing its 2026 outlook, citing fewer veterinary visits by pet owners. Investor concerns centered on near-term demand softness in the companion animal market. Despite this, management maintains a strong long-term view supported by a broad portfolio. The company has multiple growth drivers and a robust pipeline targeting undertreated conditions. Long-term fundamentals remain intact despite near-term pressure. BSD Analysis: Zoetis operates in animal health where demand is emotionally sticky and pricing power is real. Pet owners don't delay treatment the way they delay electronics purchases. The portfolio spans livestock and companion animals, smoothing economic cycles. Innovation is incremental but defensible, protecting margins. Competition exists, yet switching products often risks outcomes veterinarians won't gamble with. Growth is steady, not explosive — exactly what infrastructure looks like. Capital allocation remains disciplined. This is not a biotech lottery ticket. It's healthcare for animals with predictable compounding.” | BULL | Q4 2025 Dec 31, 2025 | View Pitch |
Brown Advisory Large-Cap Growth Strategy Brown Advisory LLC | “Zoetis underperformed this year amid intensifying competition and continued headwinds from its pain product, Librela. Aggressive promotional activity in key categories further pressured growth, and near-term prospects remain muted until new product launches materialize. Given these challenges, we exited the position to fund an investment in Danaher Corporation. BSD Analysis: Zoetis' moat is scientific depth and brand trust in animal health where outcomes matter more than price. Companion animal care provides resilient demand and strong pricing power. Livestock exposure adds cyclicality but diversifies revenue streams. Innovation cadence sustains growth, though patent cliffs still arrive on schedule. Competition exists, but switching is cautious when veterinarians trust protocols. Margins are strong, yet R&D intensity must remain high. The bull case is continued premiumization in companion animals. The bear case is spending sensitivity during broader consumer stress. Zoetis compounds by being the standard of care.” | BEAR | Q4 2025 Dec 31, 2025 | View Pitch |
Mott Capital Management Michael Kramer | “Although outside the second quarter timeframe, we added Zoetis to the portfolio on July 1. Zoetis specializes in veterinary pharmaceuticals, and pet owners likely recognize many of their products. The surge in pet ownership during the pandemic has expanded the company's addressable market, as pets age and require increased medical care, driving higher healthcare costs. Zoetis offers a compelling investment case due to its stable growth trajectory, strong profit margins, and current undervaluation in a market segment that has fallen out of favor, making its shares attractively priced at levels not seen in years. :contentReference[oaicite:2]{index=2} BSD Analysis: Zoetis is the world's premier animal-health company, benefiting from the durability of pet spending and livestock productivity demands. Its portfolio of vaccines, dermatology treatments, and parasiticides has pricing power and strong recurring revenue. Pet ownership and premiumization trends create a structural tailwind. Margins are consistently high due to scale and formulation expertise. Regulatory barriers in animal health are real, keeping competition rational. Zoetis is a defensive growth compounder hiding inside a niche healthcare category. When consumer staples feel stale, Zoetis feels alive.” | BULL | Q2 2025 Aug 4, 2025 | View Pitch |
Aristotle Core Equity Fund Mr. Fitzpatrick | “We sold Zoetis, as concerns continue to grow about competitive entrants in the dermatology and parasiticides animal health marketplace. While the company has continued to execute well in the face of new entrants, we believe that this will continue to be an overhang on the stock in the near to medium term. Given the premium valuation versus other areas in health care, we believe there is more upside eLondon Stock Exchangewhere and are exiting our position in the stock. BSD Analysis: Zoetis is the animal health empire with economic characteristics pharma companies would kill for: sticky customer relationships, recurring demand from both pets and livestock, and minimal patent-cliff drama. Its dermatology franchise continues to outperform, vaccines are steady, and new products keep replenishing the pipeline without the volatility of human drug cycles. Pricing power is real in vet channels, and companion animal demand has proven far more resilient than skeptics assumed post-pandemic. With margins at the high end of healthcare and growth visibility extending years out, Zoetis remains one of the cleanest long-term compounders in life sciences — still trading below its strategic value.” | BULL | Q2 2025 Jun 30, 2025 | View Pitch |
Aristotle Atlantic Core Equity Strategy Mr. Fitzpatrick | “We sold Zoetis, as concerns continue to grow about competitive entrants in the dermatology and parasiticides animal health marketplace. While the company has continued to execute well in the face of new entrants, we believe that this will continue to be an overhang on the stock in the near to medium term. Given the premium valuation versus other areas in health care, we believe there is more upside eLondon Stock Exchangewhere and are exiting our position in the stock. BSD Analysis: Zoetis is the undisputed king of animal health, and the tailwinds behind it are powerful: rising pet ownership, humanization of pets, and growth in protein demand globally. Its product portfolio spans companion animals and livestock with vaccines, anti-infectives, dermatology, and diagnostics — all high-margin, high-loyalty categories. Vet practices trust Zoetis brands and don't like switching, which makes revenue resilient and pricing power very real. R&D productivity has been strong, with multiple new product launches driving incremental growth on top of a sticky base. The business behaves like a pharma franchise with less patent-drama and better demand visibility. Zoetis is one of the cleanest long-term compounders in healthcare — and still not fully priced like it.” | BULL | Q2 2025 Jun 30, 2025 | View Pitch |
Each excerpt above is the manager's commentary on this ticker specifically. The full letter has the rest of their portfolio thinking, risk discussion, and broader institutional context.
